SCHEMBL2164276

SCHEMBL2164276

N#Cc1c(F)cccc1OCC1CCN(c2ccccc2Cl)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DCPS Q96C86 4/20 0.53
KDM4E B2RXH2 3/20 0.52
GAA P10253 1/20 0.46
ALDH1A1 P00352 2/20 0.45
HPGD P15428 1/20 0.45
HSD17B10 Q99714 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
DRD2 P14416 2/20 0.42
HTR2A P28223 1/20 0.42
HRH1 P35367 1/20 0.42
MEN1 O00255 1/20 0.42
TSHR P16473 1/20 0.42
KMT2A Q03164 1/20 0.42
GRM2 Q14416 3/20 0.41
CYP2D6 P10635 1/20 0.40
ADRA1D P25100 1/20 0.40
ADRA1A P35348 1/20 0.40
ADRA1B P35368 1/20 0.40
MTOR P42345 1/20 0.40
RPTOR Q8N122 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2164445 0.92 KDM4E (0.55) DCPSKDM4EALDH1A1HPGDHSD17B10
SCHEMBL1154384 0.82 KDM4E (0.46) DCPSKDM4EALDH1A1HPGDHSD17B10
SCHEMBL1154912 0.82 HSD11B1 (0.52) GAAHTR2AKMT2A
SCHEMBL2164306 0.81 HSD11B1 (0.41) DCPSKDM4EMEN1KMT2AGRM2
SCHEMBL1154431 0.80 MCHR1 (0.45) KDM4EKCNN4
SCHEMBL1154568 0.80 MCHR1 (0.45) KDM4EKCNN4
SCHEMBL30175284 0.80 MCHR1 (0.45) KDM4EKCNN4
SCHEMBL1154425 0.79 MCHR1 (0.46) KDM4EKCNN4
SCHEMBL1155201 0.78 DCPS (0.57) DCPSHRH1MEN1KMT2A
SCHEMBL2164824 0.77 SLC6A9 (0.43) DCPSKDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2069316-B1 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY FAMILIES OF SPINAL MUSCULAR ATROPHY (US) 2015-10-07 EP disclosed
EP-2615086-A1 2,4-Diaminoquinazolines for the treatment of spinal muscular atrophy Families of Spinal Muscular Atrophy (US) 2013-07-17 EP disclosed
US-7985755-B2 2,4-diaminoquinazolines for spinal muscular atrophy FAMILIES OF SPINAL MUSCULAR ATROPHY (US) 2011-07-26 US disclosed
US-20090042900-A1 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY DECODE CHEMISTRY, INC. (US) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042900-A1 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY SMN1; SMN2, MUSK, MYT1 DCPS 1366/4885KDM4E 548/4885GAA 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.